Patents by Inventor Tanja Fauti

Tanja Fauti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210230278
    Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 29, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Tina Weinzierl, Lydia Jasmin Hanisch, Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Stefan Klostermann, Christian Klein, Simon Patrick Keiser, Tanja Fauti, Estelle Marrer-Berger, Pablo Umaña
  • Publication number: 20210070873
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10851171
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 1, 2020
    Assignee: ENGMAB SARL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20200347147
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 23, 2020
    Publication date: November 5, 2020
    Inventors: Marina BACAC, Tanja FAUTI, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Ekkehard MOESSNER, Michael MOLHOJ, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Publication number: 20200306373
    Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
  • Patent number: 10766967
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 8, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Publication number: 20200255521
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? (further named also as “CD3”) and the extracellular domain of human ROR1 (further named also as “ROR1”), characterized in that the bispecific antibody does not internalize in a cell based assay at 37° C. during 2 hrs, using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, whereby not internalize means, that the mean fluorescence intensity (MFI), as detected by flow cytometry, of a bispecific antibody upon binding to ROR1-positive primary B-CLL cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re-measured after a 2 hr-incubation at 37° C. and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or B-cell disorders expressing ROR1 and ROR1-positive solid tumors.
    Type: Application
    Filed: January 27, 2020
    Publication date: August 13, 2020
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Tanja Fauti, Ramona Murr, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20200199234
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • Patent number: 10253104
    Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: April 9, 2019
    Assignee: ENGMAB AG
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Patent number: 10087250
    Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: October 2, 2018
    Assignee: Roche Glycart AG
    Inventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umaña
  • Publication number: 20180273643
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 27, 2018
    Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane Neumann, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
  • Patent number: 10077315
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? and human BCMA, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 18, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20180222991
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Inventors: Minh Diem VU, Klaus STREIN, Ekkehard MOESSNER, Ralf HOSSE, Oliver AST, Anne FREIMOSER-GRUNDSCHOBER, Marina BACAC, Tanja FAUTI, Christian KLEIN, Pablo UMANA, Samuel Moser
  • Patent number: 9963513
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 8, 2018
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20170327579
    Abstract: A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3?, characterized in comprising a common antibody light chain is provided. Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 16, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, MARINA BACAC, PETER BRUENKER, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RAFT HOSSE, ADRIAN HUGENMATTER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, Samuel MOSER, Pablo UMANA
  • Publication number: 20170306036
    Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody.
    Type: Application
    Filed: August 3, 2015
    Publication date: October 26, 2017
    Applicant: ENGMAB AG
    Inventors: Minh Diem VU, Klaus STREIN, Oliver AST, Marina BACAC, Lydia Jasmin HANISCH, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Samuel MOSER, Ramona MURR, Pablo UMANA, Sabine JUNG-IMHOF, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg REGULA, Wolfgang SCHAEFER
  • Publication number: 20170306044
    Abstract: Bispecific antibodies against CD3epsilon and ROR1 are useful for use in the treatmentof ovarian cancer.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN kLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
  • Publication number: 20170306018
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 26, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN KLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
  • Publication number: 20170198043
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 20, 2016
    Publication date: July 13, 2017
    Applicant: Roche Glycart AG
    Inventors: Johannes Auer, Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Wolfgang Schaefer, Claudio Sustmann, Pablo Umana
  • Publication number: 20170190783
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: July 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christianne Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana